Comparative Pharmacology
Head-to-head clinical analysis: CINTICHEM TECHNETIUM 99M HEDSPA versus MACROTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CINTICHEM TECHNETIUM 99M HEDSPA versus MACROTEC.
CINTICHEM TECHNETIUM 99M HEDSPA vs MACROTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m medronic acid (HEDSPA) is a diagnostic radiopharmaceutical that localizes in bone by chemisorption to hydroxyapatite crystals, allowing imaging of areas of increased osteogenic activity.
Not applicable for diagnostic use.
370-740 MBq (10-20 mCi) intravenously as a single dose for bone imaging.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for the 99mTc complex, reflecting rapid renal clearance; clinically, imaging is performed 2-4 hours post-injection.
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Primarily renal; 85-90% of injected dose eliminated in urine within 24 hours.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical